Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Non-Current Debt (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Non-Current Debt data on record, last reported at $47.8 million in Q3 2025.

  • For Q3 2025, Non-Current Debt fell 8.96% year-over-year to $47.8 million; the TTM value through Sep 2025 reached $47.8 million, down 8.96%, while the annual FY2024 figure was $58.0 million, 4.76% down from the prior year.
  • Non-Current Debt reached $47.8 million in Q3 2025 per FBIO's latest filing, down from $50.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $91.7 million in Q4 2022 and bottomed at $42.6 million in Q3 2021.
  • Average Non-Current Debt over 5 years is $62.0 million, with a median of $56.4 million recorded in 2025.
  • Peak YoY movement for Non-Current Debt: skyrocketed 114.16% in 2022, then tumbled 49.77% in 2023.
  • A 5-year view of Non-Current Debt shows it stood at $42.9 million in 2021, then skyrocketed by 113.64% to $91.7 million in 2022, then tumbled by 33.66% to $60.9 million in 2023, then dropped by 4.76% to $58.0 million in 2024, then decreased by 17.58% to $47.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $47.8 million in Q3 2025, $50.0 million in Q2 2025, and $56.4 million in Q1 2025.